The initial success of Sildenafil undeniably transformed the medication landscape, but betting in companies strongly reliant on unbranded versions presents a challenging picture. While early returns were significant, the expiration of patents and the emergence of less expensive alternatives have diminished the customer base. Consequently, a thoroug